Cargando…
Reduced Claudin-12 Expression Predicts Poor Prognosis in Cervical Cancer
Background: Within the claudin (CLDN) family, CLDN12 mRNA expression is altered in various types of cancer, but its clinicopathological relevance has yet to be established due to the absence of specific antibodies (Abs) with broad applications. Methods: We generated a monoclonal Ab (mAb) against hum...
Autores principales: | Rahman, Abidur, Kobayashi, Makoto, Sugimoto, Kotaro, Endo, Yuta, Kojima, Manabu, Furukawa, Shigenori, Watanabe, Takafumi, Soeda, Shu, Hashimoto, Yuko, Fujimori, Keiya, Chiba, Hideki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038723/ https://www.ncbi.nlm.nih.gov/pubmed/33917356 http://dx.doi.org/10.3390/ijms22073774 |
Ejemplares similares
-
Claudin-9 is a novel prognostic biomarker for endometrial cancer
por: Endo, Yuta, et al.
Publicado: (2022) -
Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer
por: Kojima, Manabu, et al.
Publicado: (2020) -
Addendum: Manabu, K., et al. Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer. Cancers 2020, 12, 2748
por: Kojima, Manabu, et al.
Publicado: (2021) -
SPON1 is an independent prognostic biomarker for ovarian cancer
por: Miyakawa, Ryoya, et al.
Publicado: (2023) -
Prediction of lymphovascular space invasion in endometrial cancer using the 55-gene signature selected by DNA microarray analysis
por: Watanabe, Takafumi, et al.
Publicado: (2019)